• BTC $9,634.45 (-5.97%)
  • ETH $203.92 (-5.76%)
  • MARKET CAP $265B
  • ICOs 4,234

Dermavir

ENDED 299 views
5.3
Total Rate

We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy platform for the treatment of chronic viral infections, cancer and allergy. Our technology is designed to boost specific immune response in order to modify or control presently incurable diseases. Our proprietary Vaccine Platform includes a given disease’s antigen specific plasmid DNA (pDNA), a nanomedicine formulation which encapsulates the pDNA to make it closely resemble a virus (we call this combination a nanoparticle), a topical (through the skin) administration device we call DermaPrep which delivers the vaccine via dendritic cell to lymph nodes of the immune system, and a software product which allows us to design antigen specific pDNA and closely match it to a patient’s genetic and HLA profile. The combination of these technologies supports the rapid and cost-effective development of original biologic vaccine products.
General
Website: Visit
White paper: Read
Pre-sale Time: 30 Mar, 2018 - 15 May, 2018
ICO Time: 15 May, 2018 - 30 May, 2018
Whitelist/KYC: Kyc
Country: USA
Token Info
Ticker: DER
Platform: Ethereum
Token type: ERC 20
Available for sale: 10,000,000 DER
Financial
Pre-sale Price: 1 DER = 0.70 USD
ICO Price: 1 DER = 1 USD
Accepting: ETH
Hard cap: 10 000 000 DER
Social Media

Viktor Rozsnyay

Chief Executive Officer

Peter Boros

Chief Operations Officer

Put this code to your website

Width: 420px-Height: 210px
comments powered by Disqus
Hot and trending ICOs
This website is using cookies. More info.